Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anakinra plus FOLFIRINOX in metastatic pancreatic cancer
NCT02021422Phase 1Completed
- Sponsor
- Baylor Scott & White Research Institute
- Start
- Dec 2013
- Primary completion
- Dec 2017
- Countries
- 1
01
Overview
Phase 1, open-label trial of anakinra in pancreatic ductal adenocarcinoma (PDAC), sponsored by Baylor Scott & White Research Institute. Primary endpoint: Number of Participants with Serious Adverse Events and Adverse Events at 6 months. Started Dec 2013; status: completed.
02
Drugs
anakinra
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02021422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02021422.